BRIACELL THERAP Debt/Equity

Debt/Equity of BCTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.

Highlights and Quick Summary

  • Debt/Equity for the quarter ending October 31, 2022 was 0.0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Debt/Equity decreased by NaN%
  • Annual Debt/Equity for 2022 was 0.0 (a NaN% decrease from previous year)
  • Annual Debt/Equity for 2021 was 0.0 (a -100.0% decrease from previous year)
  • Annual Debt/Equity for 2020 was -0.06 (a -86.39% decrease from previous year)
Visit stockrow.com/BCTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Equity of BRIACELL THERAP

Most recent Debt/Equityof BCTX including historical data for past 10 years.

Interactive Chart of Debt/Equity of BRIACELL THERAP

BRIACELL THERAP Debt/Equity for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.0 0.0 0.0 0.0 0.0
2021 0.0 0.0 0.0 -0.03 0.0
2020 -0.08 -0.06 -0.08 -0.07 -0.06
2019 0.0 -0.47 0.48 -0.81 -0.47
2018 2.28 1.19 0.42 0.0 1.19
2017 0.0 0.0 0.0 0.0 0.0
2016 0.0 0.0 0.0 0.0 0.0
2015 0.0 0.0 0.0 0.0 0.0
2014 0.0 0.0 0.0 0.0 0.0
2013 0.0 0.0 0.0 0.0 0.0
2012 0.0 0.0 0.0 0.0 0.0

Business Profile of BRIACELL THERAP

Sector: Healthcare
Industry: Biotechnology
© stockrow.com